Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health Inc GH
News
Guardant Health Prices $500 Million Convertible Senior Notes Offering
Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Kevin Sayer Joins Guardant Health Board of Directors
Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
United States